This study also elucidated the regulatory network of LINC00963/miR-320a/XBP1 and its biological function in tumor development, suggesting that both LINC00963 and miR-320a could be potential therapeutic targets for the molecular targeted therapy of DLBCL. This evidence concerns the gene XBP1 and diffuse large B-cell lymphoma.